Compare FSP & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | RLYB |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 75.9M |
| IPO Year | 2001 | 2021 |
| Metric | FSP | RLYB |
|---|---|---|
| Price | $0.63 | $15.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 552.7K | 55.9K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | $858,000.00 |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $0.50 | $0.30 |
| 52 Week High | $1.82 | $17.57 |
| Indicator | FSP | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 66.27 |
| Support Level | $0.58 | $0.56 |
| Resistance Level | $0.70 | $17.57 |
| Average True Range (ATR) | 0.06 | 0.60 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 51.01 | 52.77 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.